In vitro carboplatin-mesna interaction in aqueous solution, human plasma and urine

Area of Science:

• Pharmacology
• Oncology
• Drug Interactions

Background:

• Synergistic drug combinations and higher dosages offer chemotherapeutic benefits for cancer patients.
• Dose-limiting toxicities of drug combinations pose a significant challenge in cancer treatment.
• Sodium 2-mercaptoethane-sulfonate (mesna) is a chemoprotective agent that may mitigate carboplatin-induced nephrotoxicity.

Purpose of the Study:

• To evaluate and compare the in vitro interaction between mesna and carboplatin in aqueous solution, human plasma, and urine.
• To determine if mesna affects the stability and pharmacokinetics of carboplatin.

Main Methods:

• Carboplatin and mesna were incubated together and separately in human plasma and urine at clinically relevant concentrations.
• Carboplatin concentrations were analyzed using High-Performance Liquid Chromatography (HPLC).
• The decay and half-life of carboplatin alone and in combination with mesna were compared.

Main Results:

• Incubation of carboplatin with mesna in human plasma for up to 8 days showed no statistically significant interaction (half-life: 1.62 ± 0.08 days with mesna vs. 1.85 ± 0.04 days alone).
• In human urine, carboplatin's half-life was 3.43 ± 0.8 days alone and 2.78 ± 0.7 days with mesna over 15 days.
• A statistically significant difference in urine half-life was observed, but it is not considered clinically significant within the first 48 hours.

Conclusions:

• Mesna and carboplatin do not exhibit significant interactions in human plasma.
• The observed interaction in urine is unlikely to be clinically significant, particularly within the critical initial treatment period.
• Mesna is unlikely to substantially alter carboplatin pharmacokinetics when administered concurrently in combination chemotherapy regimens.